June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Expression profiles of potentially angio-modulative microRNAs in the mouse model of oxygen-induced retinopathy (OIR)
Author Affiliations & Notes
  • Martin Busch
    Department of Ophthalmology, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Anna Wenzel
    Department of Ophthalmology, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Johanna M Pfeil
    Department of Ophthalmology, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Andreas Stahl
    Department of Ophthalmology, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Footnotes
    Commercial Relationships   Martin Busch Bayer, Code F (Financial Support), Bayer, Code R (Recipient); Anna Wenzel None; Johanna Pfeil Novartis, Code R (Recipient); Andreas Stahl Bayer, Novartis, Code F (Financial Support), Bayer, Novartis, Alcon, Apellis, Roche, Code R (Recipient)
  • Footnotes
    Support  Research Grant from Bayer (Deutsches Förderprogramm für Augenheilkunde 2021)
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1234. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Martin Busch, Anna Wenzel, Johanna M Pfeil, Andreas Stahl; Expression profiles of potentially angio-modulative microRNAs in the mouse model of oxygen-induced retinopathy (OIR). Invest. Ophthalmol. Vis. Sci. 2023;64(8):1234.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In a previous in vitro study, we identified several miRNAs that exhibited altered expression profiles after angiogenic stimulation of retinal microvascular endothelial cells and were shown to be associated with angiogenesis-related pathways. In the present study, we analyzed expression profiles of these miRNAs at distinct phases of the oxygen-induced retinopathy (OIR) mouse model.

Methods : To induce OIR, C57BL/6J mice were exposed to 75% oxygen from postnatal day (p) 7 to p12 and then maintained under normal room air conditions. Control mice were kept under room air conditions throughout. At p12, p17, and p25, one eye of each mouse was harvested to prepare retinal flatmounts to analyze retinal vascular changes. From the contralateral eye, total RNA was isolated and reverse transcribed into cDNA for relative quantification of miRNA expression using qRT-PCR. An in situ hybridization technique (miRNAscopeTM) was used to visualize miR-21-5p expression on formalin-fixed, paraffin-embedded mouse eye tissue sections.

Results : Compared to the control group, the expression of miRNAs miR-126-3p, -126-5p, -210-3p, and -335-3p was downregulated in the OIR group at p12, when vaso-obliteration (VO) is observed in the retina, and was upregulated in the neovascular (NV) phase at p17 as well as in the phase of NV regression and revascularization of the vaso-obliterated retina at p25. The expression of miRNAs miR-21-5p, -23a-3p, 27b-3p, -139-5p, and -146a-5p was upregulated in OIR at p17 and p25, but not altered at p12. In both, the OIR and control group, miR-21-5p expression could be localized to individual cells of the retinal inner nuclear layer and ganglion cell layer. In the OIR group, however, a pronounced miR-21-5p expression could in addition be detected in cells of the superficial vascular layer of the retina at p17 and p25 and in neovascular tufts at p17.

Conclusions : We identified regulated miRNAs in ocular tissues during ischemic retinopathy, which may represent novel biomarkers and target molecules for treatment in ischemia-associated retinal pathologies such as retinopathy of prematurity and diabetic retinopathy.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×